Literature DB >> 27375015

Endogenous GABAA receptor activity suppresses glioma growth.

A Blanchart1, R Fernando1, M Häring1, N Assaife-Lopes1, R A Romanov2, M Andäng3, T Harkany1,2, P Ernfors1.   

Abstract

Although genome alterations driving glioma by fueling cell malignancy have largely been resolved, less is known of the impact of tumor environment on disease progression. Here, we demonstrate functional GABAA receptor-activated currents in human glioblastoma cells and show the existence of a continuous GABA signaling within the tumor cell mass that significantly affects tumor growth and survival expectancy in mouse models. Endogenous GABA released by tumor cells, attenuates proliferation of the glioma cells with enriched expression of stem/progenitor markers and with competence to seed growth of new tumors. Our results suggest that GABA levels rapidly increase in tumors impeding further growth. Thus, shunting chloride ions by a maintained local GABAA receptor activity within glioma cells has a significant impact on tumor development by attenuating proliferation, reducing tumor growth and prolonging survival, a mechanism that may have important impact on therapy resistance and recurrence following tumor resection.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27375015     DOI: 10.1038/onc.2016.245

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

1.  Association of polymorphisms of CYP11B2 gene -344C/T and ACE gene I/D with antihypertensive response to angiotensin receptor blockers in Chinese with hypertension.

Authors:  Hongtao Gong; Liying Mu; Tong Zhang; Xiuying Xu; Fenghe Du
Journal:  J Genet       Date:  2019-03       Impact factor: 1.166

2.  The effect of dichloroacetate on male rat thymus and on thymocyte cell cycle.

Authors:  Jurate Stanevičiūtė; Daiva Urbonienė; Angelija Valančiūtė; Ingrida Balnytė; Astra Vitkauskienė; Brigita Grigalevičienė; Donatas Stakišaitis
Journal:  Int J Immunopathol Pharmacol       Date:  2016-10-14       Impact factor: 3.219

3.  Synaptic Communication in Brain Cancer.

Authors:  Michelle Monje
Journal:  Cancer Res       Date:  2020-05-07       Impact factor: 12.701

Review 4.  Therapeutically leveraging GABAA receptors in cancer.

Authors:  Debanjan Bhattacharya; Vaibhavkumar S Gawali; Laura Kallay; Donatien K Toukam; Abigail Koehler; Peter Stambrook; Daniel Pomeranz Krummel; Soma Sengupta
Journal:  Exp Biol Med (Maywood)       Date:  2021-10

Review 5.  Neurotransmitters: emerging targets in cancer.

Authors:  Shu-Heng Jiang; Li-Peng Hu; Xu Wang; Jun Li; Zhi-Gang Zhang
Journal:  Oncogene       Date:  2019-09-16       Impact factor: 9.867

6.  The bright and the dark side of myelin plasticity: Neuron-glial interactions in health and disease.

Authors:  Michelle Monje; Ragnhildur Thóra Káradóttir
Journal:  Semin Cell Dev Biol       Date:  2020-12-05       Impact factor: 7.499

7.  LncRNA FOXD1-AS1 acts as a potential oncogenic biomarker in glioma.

Authors:  Yuan-Feng Gao; Jun-Yan Liu; Xiao-Yuan Mao; Zheng-Wen He; Tao Zhu; Zhi-Bin Wang; Xi Li; Ji-Ye Yin; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  CNS Neurosci Ther       Date:  2019-05-17       Impact factor: 5.243

Review 8.  Emerging intersections between neuroscience and glioma biology.

Authors:  Erik Jung; Julieta Alfonso; Matthias Osswald; Hannah Monyer; Wolfgang Wick; Frank Winkler
Journal:  Nat Neurosci       Date:  2019-11-12       Impact factor: 24.884

9.  Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.

Authors:  Jiajie Lu; Yuecheng Peng; Rihong Huang; Zejia Feng; Yongyang Fan; Haojian Wang; Zhaorong Zeng; Yunxiang Ji; Yezhong Wang; Zhaotao Wang
Journal:  BMC Cancer       Date:  2021-06-23       Impact factor: 4.430

10.  A GLO10 score for the prediction of prognosis in high grade gliomas.

Authors:  Feng Chen; Peng Peng; Yi Zhou; Zhen-Yu Yang; Hai-Quan Zhang; Xiang-Sheng Ao; Da-Quan Zhou; Chun-Xiang Xiang
Journal:  Oncotarget       Date:  2017-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.